

A young girl with long dark hair tied in a ponytail with a blue bow is whispering into the ear of a middle-aged man with short grey hair. The man is smiling and looking upwards. The background is a soft, out-of-focus yellowish-brown.

Urimon's mission is to free the world
from late stage diagnoses

By analyzing your body's signals,
we can detect diseases earlier

A story about signals.....



.....diseases often **don't give (early) signals** that you can feel or see

and people often **miss disease signals**

Late-stage disease detection leads to loss of life and increased costs

1 50% of cancers and CVD's are detected at advanced stage!



2 With early detection:

Survival rates:	UP	→	Stage 1 cancer: 60 - 98%	vs	Stage 4 cancer: 6 - 23%
Healthcare costs:	DOWN	→	@ €7.000 – €83.000	vs	@ € 105.000 – 390.000

The solution is a personalized Multi Disease Early Warning System (MDEWS)



Easy and noninvasive sample collection @ home



Personalized analysis in stead of population average



Cost effective → multiple organs @ once




9 disease panels @ av. sensitivity of 85%

The URIMON urine test



We use microRNAs as biomarker for disease onset

- 1 Balancekeepers:** turned on in case of organ disruption.
- 2 Only 2.000 microRNA's** so algorithms are explainable.
- 3 One measurement,** low cost, multi disease detection.



	Complexity	More than cancer	Cost-effective
MicroRNA	Low	Yes	Yes
Tumor DNA	High	No	No

Via the URIMON study we acquire early and personalized disease samples

The Urimon study: Unique samples that capture the early stages of disease



- Since 2019: > **5.000** participants, > **200.000** samples
- Healthy at start
- Age 45+, M/F
- Urine, Blood, Health data



242 cancer and 264 CVD cases, and growing...

A preliminary business model will secure timely revenue


Revenue Model



Earlyvangelists among Urimon participants and existing partnerships




We are lowering costs for broad application & reimbursement



achmea ONVZ menzis
VERZEKERD VAN JEZELF
GGD National Institute for Public Health and the Environment
Ministry of Health, Welfare and Sport
bevolkingsonderzoek nederland
Screening saves lives
Don't be the one missing out...

*Through automation costs of microRNA profiling **can be brought down to ~€25** to become eligible for reimbursement and population screening*

USPs: Sensitivity @ early detection, ease of use & multiple diseases in one test



Regulatory strategy in place & competitive advantage on multiple subjects

Regulatory strategy in place & structured dialogue
Health data provider → diagnostics provider



Gert de Vries



Charlotte Hess



Competitive advantage:

1. Unique sample- & data collection
2. Use of MicroRNA profiles for disease detection
3. MicroRNA preservation, isolation & NGS profiling
4. MicroRNA panels & algorithms



Barend Bouma



Exclusive licence from AUMC on 2 & building a patent portfolio around 3 & 4

The URIMON team has all the expertise to reach her goals



Bram de Moor LLM MBI
Business Model & Go 2 Market

- 12 yrs+ business development in LSH: 3 start-ups
- **Legal and international marketing & sales expert** in FMCG
- Multiple marketing prizes



Johan de Rooij PhD MBI
R&D & RaQa compliance

- 20 yrs+ cancer biologist
- **Biomarker science**
- Research leader & multiple start ups
- **RaQa experience**



Dr. Julia Hermann
Ethics of early disease detection
University of Twente



Dr. Hinne Rakhorst MD
Health data and registries
surgeon oncology, MST Hospital



Jeffrey Benistant MSc
Database management

- 15 yrs+ programming & medical data
- **Data safety and database management**
- Founder Osasense



Maaïke Dekker MSc
Molecular biology

- **Next Gen Sequencing (NGS)**
- Urine & blood chemistry
- Bio informatics



Dr. Michiel Pegtel
Biomarker science
Amsterdam UMC



Dr. Karin Oudshoorn
Modeling & machine learning

- 20 years+ mathematical statistics
- HTA, data visualisation
- **Machine learning & prediction models**



Diemer Harbers BSc
Laboratory and quality

- Body fluid processing
- **Quality management**
- Analytical chemistry
- Bio informatics




Jannie van den Broek
Go-to-market-strategy
North Star Advice



The ask & milestones to reach the market

Raising **€ 3,5 M** to reach next value inflection in 2026 (validation)
€ 1 M committed by current investors.
Raising subsequent **€ 3,5 M** to enter the market in 2027



Using urine for disease detection is already very old.....



De piskijker, Jan Steen 1633 - 1635

.....and we are bringing it to the 21st century!

Will you join us on our mission?



▲ Johan de Rooij (L) en Bram de Moor (R) willen naar 10.000 deelnemers aan het onderzoek. „Mensen die nu al betrokken zijn, willen iets voor de maatschappij doen”, ontdekten ze. © Robin Hilberink

SUMMARY:

1. Urine test for the early detection of disease.
2. MicroRNAs as biomarkers.
3. Unique study & biobank with early stage samples as resource for validation.
4. Raising € 3,5 M of which € 1 M secured.

Bram de Moor
+31.629.09.23.93

www.urimon.nl
bdemoor@urimon.nl

A young girl with long dark hair tied in a ponytail with a blue bow is whispering into the ear of a smiling man. The man is looking upwards and to the right. The background is a soft, out-of-focus light brown color.

Urimon's mission is to free the world
from late stage diagnoses

By analyzing your body's signals,
we can detect diseases earlier